$4.52
-0.02 (-0.44%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PASG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 3 tracked-famous managers (CITADEL ADVISORS LLC, Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 4.5 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 GenesNCT04747431Number of Participants with Treatment-Related AEs and SAEsNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: PBFT02 | Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72 | 30 | Aug 2028 | ≤ 743 d | 2026-05-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19